Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02116803
- Locations
- 🇪🇸
Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain
Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- Syndax Pharmaceuticals
- Registration Number
- NCT02115594
- Locations
- 🇺🇸
Tennessee Oncololgy, Nashville, Tennessee, United States
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 669
- Registration Number
- NCT02107703
- Locations
- 🇲🇽
OCA Hospital, Monterrey, Nuevo León, Mexico
🇺🇸Kaiser Permanente, Riverside, California, United States
🇺🇸University of California - San Diego, La Jolla, California, United States
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT02088684
- Locations
- 🇺🇸
Sarah Cannon Research Institute Onc Dept, Nashville, Tennessee, United States
🇺🇸University of Alabama at Birmingham/ Kirklin Clinic Dept Onc, Birmingham, Alabama, United States
🇺🇸Dana Farber Cancer Institute Onc. Dept., Boston, Massachusetts, United States
The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2014-02-26
- Target Recruit Count
- 180
- Registration Number
- NCT02072512
- Locations
- 🇨🇳
307 Hospital, Beijing, Beijing, China
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 198
- Registration Number
- NCT02057133
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Highlands Oncology Group - Duplicate 2, Rogers, Arkansas, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 118
- Registration Number
- NCT02049957
- Locations
- 🇺🇸
Henry Ford Medical Center, Novi, Michigan, United States
🇺🇸Texas Oncology, P.A. - Tyler, Tyler, Texas, United States
🇫🇷Institut Sainte Catherine, Avignon, Vaculuse, France
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 693
- Registration Number
- NCT02028507
- Locations
- 🇮🇱
Sheba Medical Center, Tel Hashomer, Israel
🇦🇹Universitätsklinik für Innere Medizin III, Salzburg, Austria
🇦🇹Landes-Krankenhaus Steyr, Steyr, Austria
Impact of Endogenous E2 on SSI and GH Rebound
- Conditions
- Interventions
- First Posted Date
- 2014-01-03
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 62
- Registration Number
- NCT02026973
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 58
- Registration Number
- NCT02000193
- Locations
- 🇨🇳
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.